Proteomics International pivots to sales with management shake-up
Proteomics International Laboratories has appointed experienced healthcare and medical technology executive David Morris as CEO and managing director to lead the commercial rollout of its Promarker diagnostic suite.
Morris steps into this role with a strong track record in the industry, including executive leadership at Cochlear, Nanosonics, Polynovo and Monash IVF.
Proteomics International has appointed healthcare and medical technology expert David Morris as the company’s new CEO and managing director.
The company says he brings proven expertise, particularly in driving business growth, international expansion, product commercialization and building high-performance teams; These capabilities are well-suited to accelerate the company’s Promarker precision diagnostics pipeline in key markets.
His appointment comes on the heels of last year’s announcement that the company’s US Reference Laboratory in Irvine, California, had received accreditation from the College of American Pathologists (CAP).
‘I would also like to acknowledge and thank Richard for his outstanding contribution to establishing Proteomics.’
Dr James Williams, head of Proteomics International Laboratories
Accreditation for testing clinical samples is known for its stringent and robust standards and is considered the gold standard for laboratory quality in the United States.
The prestigious accreditation contributes to the laboratory’s existing Clinical Laboratory Improvement Amendments (CLIA) certification and California State License, further strengthening the company’s regulatory credentials.
It will also support the commercial launch of Proteomics’ noninvasive PromarkerEso and PromarkerEndo diagnostic tests for esophageal cancer and endometriosis, respectively.
Dr James Williams, head of Proteomics International Laboratories, said: “The Board of Directors is pleased to appoint David as CEO. David brings deep commercial expertise in medical technology and a proven ability to translate innovative science into commercial results.”
